Previous 10 | Next 10 |
Nano-X Imaging (NNOX) +68% as FDA OKs 510(k) for Single Source Nanox.ARC Digital X-Ray.Chembio Diagnostics (CEMI) +48%.NanoVibronix (NAOV) +24%.Leaf Group Ltd. (LEAF) +19% on being acquired by Graham Holdings for $8.50 per share.dMY Technology Group (DMYD) +19%.Hoth Therapeutics (HO...
Invitae (NVTA) has entered into a definitive agreement to acquire genomics company Genosity in a bid to accelerate the time to market and decentralization of Invitae's personalized oncology offerings.Under the terms of the deal, Invitae will acquire Genosity for about $200M, consisting o...
Invitae Announces $1.15 Billion Investment Supporting Ongoing Growth Initiatives PR Newswire SAN FRANCISCO , April 5, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that a small group of investors, led by SB Ma...
Invitae to acquire Genosity to accelerate access to personalized oncology testing worldwide Acquisition to support the speed, efficiency and flexibility needed for mainstream global adoption of personalized cancer care and monitoring PR Newswire SAN FRANCISCO , ...
SoftBank Group (SFTBY) (SFTBF) is planning a $1.2B investment in Invitae (NVTA) in the form of convertible debt, the Wall Street Journal reports.The initial conversion price of $43.18 per share implies a ~20% premium to the trailing five-day average of Invitae shares. The stock...
I am a big fan of the ARK funds and Cathie Wood in particular. Upon reviewing the asset mix of the ARK Genomic Revolution Multi-Sector ETF, I came away less than enthused. The turbocharged returns seem to be a thing of the past as detailed below. For further details see: ...
Invitae shares rise (NVTA) after announcing the availability of sponsored genetic testing for patients in the U.S., Canada, Australia and Brazil at risk for developing adult neurodegenerative conditions, including Parkinson's disease ((PD)), amyotrophic...
Invitae introduces new program to increase access to genetic testing for adult neurodegenerative conditions -- New sponsored testing program can make it easier for patients to receive genetic testing in Parkinson's disease, early-onset Alzheimer's disease, ALS and other common c...
Faced with disruption from the pandemic last year and ongoing uncertainty about shifting consumer trends, many businesses are in need of help. Artificial intelligence can add a much-needed shot of predictability, efficiency, and flexibility to business operations, making it a hot item in th...
Shares of Invitae (NYSE: NVTA) were tumbling 10.9% as of 3:11 p.m. EDT on Wednesday. There weren't any new developments that explained the decline. Instead, the stock appeared to be dragged down in a broader sell-off of growth stocks. It's best to ignore short-term volatility, e...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...